Skip to main content

Advertisement

Table 3 Multivariate analyses of AML patients receiving chemotherapy only and allo-HSCT based on left-truncated Cox model

From: Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation

Variable No. of patients HR (95% CI) P value
Relapse
 Therapy
  Allo-HSCT 45 1.00  
  Chemotherapy only 43 11.49 (4.43–29.82) <0.001
 WT1 transcript levela
  High 48 1.00  
  Low 40 3.53 (1.64–7.62) 0.001
 MRD test resultb
  Negative 53 1.00  
  Positive 35 2.30 (1.06–4.97) 0.034
Treatment failure
 Therapy
  Allo-HSCT 45 1.00  
  Chemotherapy only 43 5.85 (2.75–12.44) <0.001
 WT1 transcript level
  High 48 1.00  
  Low 40 3.71 (1.82–7.56) <0.001
 MRD test result
  Negative 53 1.00  
  Positive 35 2.33 (1.17–4.64) 0.016
Mortality
 Therapy
  Allo-HSCT 45 1.00  
  Chemotherapy only 43 4.34 (1.98–9.53) <0.001
 WT1 transcript level
  High 48 1.00  
  Low 40 3.50 (1.56–7.82) 0.002
 MRD test result
  Negative 53 1.00  
  Positive 35 2.32 (1.09–4.97) 0.030
  1. HR hazard ratio, CI confidence interval, WT1 Wilm tumor gene-1, MRD measureable residual disease, RUNX1-RUNX1T1 runt-related transcription factor 1-RUNX1 translocation partner 1
  2. aPatients with WT1 transcript levels ≤5.0% and >5.0% at diagnosis were characterized as having low and high WT1 transcript levels, respectively
  3. bA less than and no less than 3-log reduction in RUNX1-RUNX1T1 transcript level compared to baseline (>0.4% and ≤0.4%) after the second cycle of consolidation chemotherapy were defined as positive and negative MRD test results, respectively